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Abstract
Emerging infectious diseases (EIDs) are an increasing threat to public health on a global scale. In recent times, the most
prominent outbreaks have constituted RNA viruses, spreading via droplets (COVID-19 and Influenza A H1N1), directly
between humans (Ebola and Marburg), via arthropod vectors (Dengue, Zika, West Nile, Chikungunya, Crimean Congo) and
zoonotically (Lassa fever, Nipah, Rift Valley fever, Hantaviruses). However, specific approved antiviral therapies and
vaccine availability are scarce, and public health measures remain critical. Patients can present with a spectrum of ocular
manifestations. Emerging infectious diseases should therefore be considered in the differential diagnosis of ocular
inflammatory conditions in patients inhabiting or returning from endemic territories, and more general vigilance is advisable
in the context of a global pandemic. Eye specialists are in a position to facilitate swift diagnosis, improve clinical outcomes,
and contribute to wider public health efforts during outbreaks. This article reviews those emerging viral diseases associated
with reports of ocular manifestations and summarizes details pertinent to practicing eye specialists.
Introduction
Emerging infectious diseases (EIDs) pose a considerable
ongoing threat to humanity. The World Health Organization
(WHO) define EIDs as those that are either novel and
severely affect a population for the first time, or those that
have existed previously but have a rapidly increasing inci-
dence or degree of spread to new geographical areas [1].
Globalisation and climate change have led to an accelera-
tion in the emergence of EID outbreaks in recent times, with
the WHO reporting 1483 epidemic events in 172 countries
between 2011 and 2018 [2]. Since infectious diseases are
increasingly extending beyond endemic territories, the
clinician should be armed with a global perspective.
Recent outbreaks combined with the development of
diagnostic techniques have increasingly allowed character-
isation of the ocular manifestations of EIDs [3]. The most
prominent outbreaks in recent times have constituted viruses
such as the 2014–2016 Ebola outbreak in West Africa,
2015–2016 Zika outbreak in the Americas, a series of
increasingly frequent Dengue outbreaks and the current
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pandemic [4–7]. With the necessary precautions, eye
specialists are therefore in a position to facilitate swift diag-
nosis, improve clinical outcomes and contribute to wider
public health efforts during outbreaks. To this end, we pro-
vide a timely review of emerging viral diseases for the oph-
thalmologist (Table 1).
Methodology
Emerging viral diseases were identified for inclusion using the
WHO list of designated ‘priority’ pathogens as well as an
initial scoping literature search for emerging viral diseases
with ocular manifestations [8]. For each virus identified for
inclusion, an in-depth literature search was performed using
MEDLINE’s database, with variations on virus name, emer-
ging disease, and ocular manifestations, as key search terms.
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Table 1 Summary table of emerging viral diseases with ocular manifestations, detailing their epidemiology and presentation, and grouped
according to primary mode of transmission. Emerging viral diseases with ocular manifestations.
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Table 1 (continued)
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Studies selected were in English and pertaining to humans.
Searches were supplemented by reviewing reference lists of
relevant papers. The viruses discussed will be grouped
according to the mechanism of transmission and family.
Human-to-human
Ebola* (Filoviridae)
Ebola virus (EBOV) is an enveloped, filamentous, negative-
sense, single-stranded RNA virus of the Filoviridae family.
EBOV is the cause of the frequently lethal Ebola virus disease
(EVD), which has a documented case fatality rate of around
50% [9]. EVD outbreaks typically start from a single case of
probable zoonotic transmission, and fruit bats, likely of the
Pteropodidae family, are believed to be the natural reservoir
for the virus. Human-to-human transmission then occurs via
direct contact, or contact with infected bodily fluids or con-
taminated fomites. The unprecedented 2013–2016 Western
African EVD outbreak (the largest in history: 28,600 cases
and 11,300 deaths) and the ongoing EVD outbreak in the
Democratic Republic of the Congo have shed light on the
spectrum of manifestations of EVD [10].
Table 1 (continued)
Emerging viral diseases with ocular manifestations.
1120 A. Venkatesh et al.
After contact with the virus, the asymptomatic incubation
period ranges from 2 to 21 days with an average of 8 to
10 days. EVD is typically characterized by an initial fever,
myalgias and fatigue, progressing to gastro-intestinal
symptoms (diarrhoea and vomiting) and eventually a fatal
multiple organ dysfunction syndrome. During acute infec-
tion, ocular manifestations include conjunctival injection
(48–58%; often bilateral), subconjunctival haemorrhages
and vision loss of unclear origin [4].
An important clinical sequel has surfaced in survivors,
termed the ‘post-Ebola virus disease syndrome’. This
commonly manifests with ocular disease (60%), and may be
accompanied by arthritis, hearing loss, abdominal pain and
neuropsychiatric disorders as well as viral persistence in
immune-privileged organs [11]. Uveitis is the most com-
mon ocular complication, occurring in ~13–34% of EVD
survivors in West Africa within the first 12 weeks (but
sometimes even after a year) following convalescence [12].
This commonly presents with eye pain, redness and pho-
tophobia and may lead to acute or chronic vision loss, with
a unilateral predominance [13]. Within uveitis, case series
quote variable prevalence statistics, overall indicating
anterior uveitis as most frequent, followed by posterior
uveitis, and rarely panuveitis [14–16]. Slit lamp examina-
tion often shows non-specific signs of active or past ocular
inflammation e.g. posterior synechiae, keratic precipitates,
anterior chamber cell and flare and conjunctival injection
[17]. Multimodal imaging including fundus photography
and optical coherence tomography (OCT) can be used to
evaluate retinal lesions in posterior or panuveitis. A case
series evaluating 14 EVD survivors noted retinal lesions
that were predominantly non-pigmented with perilesional
areas of dark without pressure, and peripapillary lesions that
exhibited variable curvatures respecting the horizontal
raphe and sparing the fovea [18]. OCT showed abnormal-
ities of the outer retinal layers (Fig. 1). In these uncontrolled
cohorts, risk factors predicting uveitis include conjunctival
injection, and a high viral load (corresponding to a low
cycling threshold on reverse transcription PCR (RT-PCR)
analysis) during acute EVD, and advanced age [11, 14]. The
PREVAIL III prospective cohort study in Liberia found that
survivors exhibited more frequent uveitis than controls, and
the prevalence increased during follow-up (at enrolment,
26.4% vs. 12.1%; at year 1, 33.3% vs. 15.4%) [19]. Neuro-
ophthalmic complications are also possible, including optic
neuropathy and ocular motility disorders [16]. Other
Fig. 1 Ebola retinal lesions. A Colour fundus image, B corresponding OCT images showing discontinuities in the outer retinal layers, C multiple
non-pigmented lesions and associated perilesional areas of dark without pressure. Source: Steptoe et al. [18] (CC-BY License).
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ophthalmic sequelae include episcleritis, interstitial keratitis
and cataract [4, 14, 15].
Diagnosis requires a combination of case definition and
laboratory tests, typically real-time RT-PCR or enzyme-
linked immunosorbent assay (ELISA). This permits the
swift initiation of appropriate cycloplegic and anti-
inflammatory treatment (topical or systemic steroids
depending on severity) for uveitis and recognition and
management of complications. Notably, the finding of
replicating EBOV in the aqueous humour following
recovery from EVD (and for at least 100 days post acute
EVD diagnosis) highlights possible infectivity of ocular
fluid posing risk to ophthalmologists performing invasive
procedures on EVD survivors [20, 21].
Timely diagnosis can help avoid long-term visual disability.
Specifically, whilst USA healthcare workers swiftly treated
recovered vision following therapy, nearly 40% of eyes in a
Liberian cohort in whom treatment was comparatively delayed
had vision worse than 20/400 than their initial presentation,
sometimes because of structural complications including cat-
aract and dense vitreous opacity [4]. In one study of 57
patients with uveitis after EVD, 7 (12%) were also diagnosed
with cataracts concurrently with uveitis, and at least 3 others
developed cataract(s) following the onset of uveitis [11]. This
illustrates that interventions to counteract the resource-limited
delays in uveitis diagnosis and treatment focussed in areas at-
risk for EVD might help to reduce the risk of vision-related
morbidity in future outbreaks. Recent evidence highlights the
feasibility of establishing screening eye clinics for EVD sur-
vivors to facilitate this objective [22].
The mainstay of treatment for the underlying EBOV
infection is currently supportive and symptomatic; however,
antiviral drugs are emerging [23]. An experimental Ebola
vaccine is now FDA-approved for the prevention of EVD in
individuals aged 18 years and older [24]. It is being used in
a ring vaccination protocol to control current outbreak in the
Democratic Republic of the Congo [9].
Marburg* (Filoviridae)
Marburg virus (MARV) is a negative-sense RNA virus of
the Filoviridae family. Zoonotic infection occurs following
prolonged exposure to Rousettus aegyptiacus bats, the
natural reservoir of MARV, with outbreaks mostly endemic
to East and Central Africa [25]. Secondary human-to-
human transmission occurs primarily via direct contact with
a symptomatic individual or their infected bodily fluids and
MARV is known to persist in immune-privileged sites
following recovery [26, 27]. After an incubation period of
2–21 days, Marburg virus disease (MVD) typically presents
abruptly with high fever, severe headache and malaise,
often with gastro-intestinal disturbance and a maculo-
papular non-pruritic rash. The development of
haemorrhagic manifestations between 5 and 7 days signals
late stage disease and case fatality rates between 23 and
90% have been recorded [28]. Ocular involvement is lim-
ited to a single case report of acute anterior uveitis devel-
oping during convalescence (3 months following acute
MVD onset), which was successfully treated with topical
steroids, atropine and acetazolamide [29, 30]. MARV can
persist after resolution of symptoms or death in various
human tissues, secretions and even immune-privileged sites.
This is a finding supported more recently by primate studies
highlighting viral persistence in the eye [27, 31]. Diagnosis
is made by RT-PCR from blood or buccal swab, and a
negative test does not rule out infection until symptoms
have been present for at least 72 h [32]. There is no specific
antiviral treatment or vaccine at present; aggressive sup-
portive care and fluid resuscitation complemented by public
health measures form the mainstay of management [27, 33].
Human herpes virus-6 (HHV-6)
HHV-6 is a double-stranded DNA virus of the β-herpes virus
subfamily found worldwide, with two variant species HHV-
6A and HHV-6B. Little is known about the acquisition or
prevalence of HHV-6A and it is less associated with disease
[34]. In contrast, HHV-6B, which has a seroprevalence
approaching 100%, with infection typically occurring in
childhood [35]. The virus replicates in the salivary glands
and is transmitted through the saliva. HHV-6 mRNA has
been detected in the ocular fluid sample of a patient with
uveitis suggesting that viral replication may occur in the eye
[36]. Additional tests for HHV-6 RNA or protein in ocular
tissues would provide more definitive evidence of this.
There are typically three stages in the natural history of
HHV-6 infection [35]. Acute primary infection in childhood
causes exanthem subitum [37], also called roseola infantum.
This is characterised by a high fever followed by a rash that
spontaneously resolves. Complications include CNS inva-
sion, hepatitis and pneumonitis, in both immunocompetent
and immunosuppressed patients. The second stage occurs in
healthy adults and children where the virus remains latent
in lymphocytes and monocytes and stays at a low level in
tissues. The third stage is due to reactivation from latency or
reinfection in immunosuppressed patients.
Ocular conditions of the posterior segment are more
commonly associated with HHV-6, though the exact role of
HHV-6 in these conditions remains unclear. Posterior seg-
ment inflammation associated with HHV-6 includes AIDS-
associated retinitis [38–41], uveitis [36, 42–46] and optic
neuritis [46–49]. The prevalence of HHV-6 in ocular fluid
samples of patients with ocular inflammation has been
found to be 2% or less [36, 42, 43]. The largest study to date
found 7/350 patients with uveitis or endophthalmitis tested
positive for HHV-6 DNA in ocular fluid samples [36]. The
1122 A. Venkatesh et al.
detection of HHV-6 DNA in the eye may not be clinically
relevant as all seven patients were found to have other
infectious agents in ocular fluid samples. Therefore, it is
assumed that HHV-6 infections play a secondary role in the
pathogenesis of ocular inflammation [36]. Presence of
HHV-6 DNA can be accounted for as it latently resides in
immune cells [35], which may enter the eye during
inflammation due to destruction of the blood–retinal barrier
[36]. Alternatively, HHV-6 DNA detected in intraocular
fluids may be due to release of HHV-6 DNA from resident
ocular cells caused by intraocular inflammation and this is
supported by findings that HHV-6 can infect human retinal
pigment epithelial cells [50].
In addition, reactivation of HHV-6 frequently accom-
panies CMV reactivation [51]. In nine patients with AIDS-
associated retinitis, three were positive for HHV-6 and all
three had simultaneous CMV coinfection [41]. This sug-
gests that presence of HHV-6 may simply reflect the
immunocompromised state of the patient.
Anterior segment disease associated with HHV-6 includes
corneal inflammation [36, 52, 53]. HHV-6 was detected in 14/
22 patients with corneal inflammation, specifically, dendritic
keratitis, corneal ulcer or keratouveitis. This study showed the
association of HHV-6 with disease is more frequent than
other herpesviruses suggesting that HHV-6 may be another
sole causative agent for corneal inflammation [52].
Diagnosis of clinically relevant HHV-6 is challenging
due to the high prevalence of infection and need to distin-
guish between active and latent infections [36]. Detection of
HHV-6 DNA in the plasma or serum indicates active
infection [54]. Quantitative PCR can distinguish between
active and latent infections of clinical samples tested, such
as aqueous humour, vitreous or corneal samples. Multiplex
PCR of the aqueous humour should be performed in sus-
pected cases for early diagnosis of HHV-6 and specific
antiviral therapy initiation [45, 46]. Foscarnet, ganciclovir,
either alone or in combination and cidofovir should be used
for management of HHV-6-related neurological disease and
seems to be more efficient than acyclovir [45, 55, 56].
Animal-to-human
Lassa fever (LF)* (Arenaviridae)
Lassa virus (LASV) is an enveloped, negative-sense, single-
stranded, bi-segmented RNA virus of the Arenaviridae
family and is endemic to West Africa. Infection often
occurs through exposure to food or household items con-
taminated with urine or faeces of infected Mastomys rats.
Person-to-person transmission may occur after exposure to
virus in bodily fluids, particularly in healthcare settings in
the absence of control measures. Following a 7–21-day
incubation period, LASV can cause Lassa fever (LF), an
acute viral haemorrhagic illness with an overall case fatality
rate of 1%, though most-affected individuals harbour the
infection asymptomatically (80%) [57]. Ocular involvement
is not extensively reported for LF, with a single case series
noting conjunctivitis and conjunctival oedema in acute LF,
whilst transient blindness has been documented during
convalescence [58–60]. Animal studies highlight high viral
loads present in the aqueous humour in rhesus macaques
that died of experimental LASV infection [30]. LF is most
often diagnosed by ELISA to detect IgM and IgG antibodies
as well as Lassa antigen. Ribavirin seems to be an effective
antiviral therapy early in the disease course, but its use as
post-exposure prophylaxis is unsupported [61, 62]. There is
currently no vaccine that protects against LF. Together,
these findings support minimal long-term effects on vision
in LF—further longitudinal studies are necessary to clarify
this association, and in the meanwhile careful ophthalmic
observation of LF survivors is recommended.
Nipah* (Paramyxoviridae)
Nipah virus is an enveloped, negative-sense, single-stranded
RNA virus in the family Paramyxoviridae of the genus
Henipavirus. It was first isolated during the 1999 outbreak
in Malaysia and Singapore. Repeated outbreaks have since
occurred in India and Bangladesh. Transmission is pri-
marily zoonotic from contact with infected pigs or bats,
though person-to-person transmission has also been repor-
ted in Bangladesh and India, highlighting its pandemic
potential [63]. There are currently no studies on viral per-
sistence in bodily fluids.
The disease has a high mortality rate of 40% (Malaysia)
to over 70% (India) [63]. Variation in mortality rates and
clinical features in the two regions are likely due to different
strains, which have separately co-evolved. The incubation
period is from 4 to 21 days, followed by up to 2 weeks of
fever and headache. Fatal encephalitis is the main compli-
cation of the disease and acute respiratory disease occurs to
varying degrees.
Regarding ocular manifestations, one small study from
Singapore of 13 patients reported nystagmus, VI nerve
palsy and transient blindness during the acute phase of the
illness [64]. Residual clinical signs at an 18-month follow-
up included nystagmus, branch retinal artery occlusion, VI
nerve palsy and Horner’s syndrome [64]. Retinal artery
involvement is consistent with the hypothesis of vasculitic
small-vessel infarction. Another study found that abnormal
doll’s-eye reflex and pin-point pupils with variable reac-
tivity were associated with a higher mortality suggesting
greater brain stem involvement [65]. These two studies
examined symptoms in pig farmers in Singapore or
Malaysia. Therefore, further characterisation of ocular
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manifestations of the more pathogenic viral strains in
Bangladesh and India is needed [66].
Diagnosis focuses on RT-PCR of throat swabs, blood,
urine and CSF [67]. There is no approved vaccine and
treatment is largely supportive with evidence for ribavirin
treatment being equivocal [65, 68].
Rift valley fever (RVF)* (Phenuiviridae)
RVF virus is an enveloped, negative-sense, single-stranded
RNA virus, of the family Phenuviridae [69]. It is the cause
of RVF, a zoonotic arthropod-borne disease, mainly
affecting cattle. With an incubation period of 2–6 days,
most human infections follow contact with the blood or
organs of infected animals, typically occupationally. A
smaller number occurs via mosquito bite (Aedes or Eret-
mapodites genus), and there are no documented cases of
human-to-human transmission [70, 71]. Outbreaks, closely
related to high-rainfall conditions, have mainly occurred in
sub-Saharan Africa and North Africa, though more recently
cases were reported in the Arabian Peninsula. In the five
most recent outbreaks for which relevant data were recor-
ded, an estimated total of 339,000 infections are believed to
have occurred [72]. Documented case fatality rates are
highly variable, though it is thought to be <1% [71].
In its most common mild form, RVF is characterised by
fever and non-specific flu-like symptoms. In a small percen-
tage of cases, a severe form develops, categorised into three
syndromic presentations: ocular disease with risk of perma-
nent loss of vision; meningoencephalitis with confusion and
potentially coma; and haemorrhagic fever with liver invol-
vement and jaundice, this being the most fatal form [73].
Ocular manifestations are well-documented, and present
symptomatically with blurred vision, decreased vision,
floaters, scotomatous areas or periocular pain [74–82]. The
classical manifestation is of macular or paramacular retinitis
(Fig. 2). It is difficult to estimate the true incidence of ocular
complications in RVF, as total case numbers in outbreaks
are not known and incidences in case series from different
outbreaks vary significantly. However, the WHO estimates
an incidence of 0.5–2% patients [71]. The largest series to
date looked at 143 patients (212 eyes) all with macular or
paramacular retinitis and serologically proved RVF in the
2000 Saudi Arabian outbreak [75]. Onset of visual symp-
toms ranged from 4 to 15 days. Associated lesions included
retinal haemorrhages (40% of eyes), vitreous retractions
(26%), optic disc oedema (15%) and retinal vasculitis (7%,
mostly phlebitis, occasionally arteritis). A single creamy-
white area of retinal necrosis was typically seen on fundo-
scopy reflecting retinitis, alongside the other described
associated lesions. Fluorescence angiography demonstrated
an early hypofluorescence of the area of retinitis
and delayed filling of arterioles and venules, with late
staining of the retinal lesion and blood vessels. Active
lesions largely resolved over a 9-month follow-up, leaving
behind chorioretinal scarring, and in some cases vascular
occlusion and optic atrophy. Seventy-one percent of eyes
remained legally blind at the end of follow-up, compared to
40–50% permanent visual loss reported in previous studies.
Fifty-one eyes also developed a transient mild-to-moderate
anterior uveitis, which appeared non-granulomatous.
RVF and its ocular manifestations may mimic other viral
diseases, and so diagnosis relies on laboratory testing with
either RT-PCR or serology [73]. No positive RVF viral
cultures or RT-PCR have been reported as yet in CSF, or on
aqueous or vitreous samples [83]. No disease-specific
treatments are available, and no vaccines are licenced or
commercially available for human use at present [71].
Severe cases are managed supportively.
Hantaviruses e.g. Hantaan, Puumala, Seoul,
Dobrava (Bunyaviridae)
Hantaviruses are enveloped, single-stranded, negative-sense
RNA viruses of the Bunyaviridae family. The viruses are
rodent-borne and transmission is via aerosols of excreta,
saliva and urine, leading to an initially non-specific viral
presentation of pyrexia, chills and myalgias following an
incubation period (10–25 days). Person-to-person trans-
mission is generally rare for hantaviruses, with the notable
exception of Andes virus (ANDV) following reports of
transmission of ANDV in the hantavirus cardiopulmonary
syndrome (HCPS) outbreak in Argentina in 1996 [84, 85].
Nowadays, hantavirus infections are subdivided into two
groups representing the two most common clinical patterns
of infection [86–88]. ‘New World’ hantaviruses are
Fig. 2 Rift Valley fever virus, fundus photograph, demonstrating
active retinitis in the macular region and retinal haemorrhages.
Source: Khairallah [231] (CC-BY licence), original publication Al-
Hazmi 2005.
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principally found in the Americas, and may cause hanta-
virus cardiopulmonary syndrome (HCPS), characterized by
interstitial pulmonary oedema leading to shock and cardi-
opulmonary failure. ‘Old World’ hantaviruses are found
mostly in Europe and Asia, and may cause haemorrhagic
fever with renal syndrome (HFRS), marked by sudden and
extreme albuminuria due to renal medullary damage, that
may lead to renal failure.
Transient ocular involvement in hantavirus infection is
now increasingly recognised, and to date, has mainly been
described in the context of HFRS caused by Puumala virus.
An acute, transient myopia may be the first and most car-
dinal ocular symptom of a hantavirus infection, and its
incidence has been variably reported (12–53%) in Puumala
virus infections in Europe [89–91]. The underlying
mechanism is unclear, but the leading theory involves an
anterior shift of the lens due to underlying inflammation of
the ciliary body [91]. Anterior shift of the lens may pre-
dispose to angle closure glaucoma, reported in exceptional
cases, and may be associated with ciliochoroidal effusion
[89, 92]. In the largest case series (46 patients) to date
reporting on ocular involvement in patients who had
recovered from acute HFRS, 70% reported ocular symp-
toms during the disease course, which were often bilateral
[93]. During the acute phase of infection, 88% experienced
decreased intraocular pressure, 87% reduced visual acuity,
87% conjunctival chemosis, 82% thickening of the lens,
78% myopic shift, 64% shallowing of the anterior chamber
and 52% shallowing of vitreous length. Aside from anterior
segment changes, macular features such as dot and blot
intraretinal haemorrhages and streak haemorrhages of the
disc have been reported on fundus imaging [94]. Recently,
the first case report of presumed hantavirus necrotizing
retinitis concurrent with HFRS was confirmed by fluor-
escein angiographic and funduscopic findings, and in this
patient visual acuity losses improved months after resolu-
tion of the infection [95]. Together, these findings highlight
that a diverse range of transient ocular disturbances in
hantavirus infection are probable, and generally resolve
with recovery from systemic infection.
At present, there are currently no approved treatments or
vaccines available for hantavirus infections [96]. Supportive
management in the intensive care unit is the current main-
stay of treatment, with better patient outcomes associated
with ICU admission earlier in the disease course (CDC).
Arboviruses
Dengue (Flaviviridae)
Dengue viruses are enveloped, positive-sense, single-
stranded, RNA viruses of the Flaviviridae family. They are
the cause of dengue fever. There are four viral serotypes
1–4 with no cross-immunity, and spread is via Aedes
mosquito vectors [97]. Incidence has increased 30-fold over
recent decades, and there are now an estimated 96 million
symptomatic infections annually, two million cases of
severe dengue, and 21,000 deaths [98–101]. Occurring in
endemic–epidemic cycles in crowded tropical urban areas,
the largest numbers of infections are in children in Asia and
young adults in the American tropics, albeit with significant
extension to other continents [102].
Dengue fever occurs 3–14 days after a mosquito bite,
with development of a non-specific febrile phase lasting
3–6 days [97]. Upon fever resolution, some cases progress
to a critical phase of plasma leakage into abdominal and
pleural cavities, also sometimes associated with impaired
haemostasis. Other findings include vomiting, petechial
rash, myalgia, hepatomegaly, lymphopenia and thrombo-
cytopenia. A convalescent phase follows. Cases of severe
dengue involve dengue shock syndrome and respiratory
distress secondary to plasma leakage, severe bleeding and
severe end organ involvement [98].
True incidence of ocular manifestations is poorly
understood, with studies only including cases that reach
hospital specialists. In such studies incidence has been
reported between 7.1 and 40.3%, a range that likely reflects
differing disease severities and differing ocular workups in
each study [103, 104]. Ocular manifestations occur from
days to months after dengue fever onset. Reported anterior
segment manifestations include, more commonly, sub-
conjunctival haemorrhages and anterior uveitis, and more
rarely, shallow anterior chambers, acute angle closure
glaucoma, superficial punctate erosions, keratitis, vitritis,
intermediate uveitis and scleritis [6, 104, 105]. Anterior
uveitis has been reported to present with eye pain, redness,
photophobia, ciliary injection, low-grade anterior chamber
cells and diffuse keratic precipitates [81].
Posterior segment manifestations most commonly
include maculopathy and posterior uveitis, and less com-
monly vascular occlusions, panuveitis and retinal and vitr-
eous haemorrhage [6]. Maculopathy, typically asymmetric
and bilateral, is reported in 10% of hospitalised patients,
and is serotype-dependent [106, 107]. Onset of symptoms in
maculopathy, such as decreased visual acuity and a central
scotoma, occur 3–11 days after fever onset, with recovery
over 2–4 weeks; though in many cases patients remain
asymptomatic [108–110]. Characteristic findings on OCT
allow subclassification into three groups: (1) diffuse retinal
thickening, (2) cystoid macular oedema and (3) foveolitis
(Fig. 3), the latter including an orange-yellow central foveal
lesion and associated with the longest persistence of sco-
tomata [108]. Other findings include retinal haemorrhages,
primarily venous vasculitic changes, and yellow sub-retinal
spots [6]. Cases of rare neuro-ophthalmic complications
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have included optic neuropathy, neuromyelitis optica and
abducens palsy [6].
Diagnosis relies upon dengue symptomatology, and
confirmation by laboratory testing. In the first 5 days, real-
time RT-PCR or NS1 antigen detection allow confirmation.
More commonly confirmation occurs after 5 days, with
ELISA-based detection of anti-Dengue IgM or ser-
oconversion in paired acute and convalescent serum sam-
ples [97]. Workup of posterior segment pathology to
identify and grade severity of complications as well as
facilitate mechanistic understanding involves visual field
testing and multimodal imaging [6]. The latter includes
fundoscopy, fluorescein and indocyanine green angio-
graphy, OCT for subclassification, and more recently OCT
angiography [108, 111]. Ocular manifestations resolve
spontaneously in the majority of cases and evidence for
topical or systemic treatment with corticosteroids lacks
consensus [6]. Vaccines in the latter development stages are
showing some promise [112].
Zika* (Flaviviridae)
Zika virus (ZIKV) is an enveloped, positive-sense, single-
stranded, RNA virus with an icosahedral capsid, and is a
member of the Flaviviridae family [113, 114]. First dis-
covered in Uganda, ZIKV has since disseminated widely
throughout Africa, Asia, Pacific islands, South and Central
America, causing notable outbreaks in Micronesia (2007),
French Polynesia (2013) and the Americas (2015–16)
[67, 109, 115].
Zika is principally transmitted via the bite of an infected
Aedes mosquito (such as A. aegypti and A. albopticus),
usually during daytime [116]. Human-to-human transmis-
sion can then occur via sexual contact, blood transfusions,
organ donation and vertically from mother to foetus [117].
Findings of viral RNA in tears and conjunctival swabs from
confirmed human cases highlight a potential ophthalmic
route of transmission [118, 119].
Infected patients are typically asymptomatic, however up
to 20% may develop a mild, self-limiting symptom triad of
generalized maculopapular rash, arthritis or arthralgia and
non-purulent conjunctivitis following a 3–14 day incubation
period [117, 120, 121]. Though rare, severe neurological
sequelae such as Guillain–Barré syndrome, myelitis and
meningoencephalitis may develop ~5 days after acute dis-
ease onset [122, 123]. Infection anytime during pregnancy
poses up to a 10% risk of the manifestation of congenital
zika syndrome (CZS) due to vertical transmission, char-
acterised by severe microcephaly, thin cerebral cortices,
retinal disease, congenital contractures and early hypertonia
and extrapyramidal involvement [124–126]. The most
severe CZS phenotype occurs following first trimester
exposure [120, 122, 127, 128].
Ocular involvement related to Zika virus may be
acquired in the acute phase or present congenitally. In the
acute phase, non-purulent conjunctivitis and retro-orbital
pain are the most frequent ocular signs, both reported in
40% in a Brazilian case series of 57 ZIKV positive patients
[129]. Reports of uveitis are uncommon (limited to under
20 published cases) and tend to have favourable visual
outcomes without recurrence [130]. Anterior uveitis may be
bilateral and non-granulomatous, and is associated with
high intraocular pressures, corneal oedema and minimal fine
keratic precipitates, responding effectively to topical corti-
costeroids and anti‐hypertensive drugs [131–133]. Posterior
uveitis may manifest as a bilateral neuroretinitis, chorior-
etinitis with placoid or multifocal non-necrotizing lesions
[134–136]. Reduced visual acuity can result from a uni-
lateral acute idiopathic maculopathy occurring in the
absence of uveitis, consisting of a unilateral perifoveolar
greyish discoloration, and resolving within 6 weeks without
treatment [137, 138].
Ocular manifestations of Zika have been described in up
to 55% of infants with CZS [139, 140]. Two characteristic
manifestations include a well-circumscribed chorioretinal
atrophy with a hyperpigmented border and focal pigment
Fig. 3 Dengue foveolitis in left
eye. A Fundus photograph
showing orange-yellow central
foveal lesion B OCT scan
demonstrating focal thickening
of the outer neurosensory retina
and retinal pigment epithelium.
Source: Khairallah [231] (CC-
BY licence), original courtesy of
Soon-Phaik Chee.
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mottling at the macula, occurring in up to 70% of children
with ocular findings [116, 140, 141]. This posterior eye
involvement is speculated to arise from viral breakdown of
the blood–retinal barrier or axonal transport along
nerves [141–144]. Numerous other ocular manifestations in
CZS are possible, including various optic disc changes,
retinal vascular disease, congenital glaucoma and cataract,
lens subluxation, microphthalmia and iris coloboma,
leading to multiple deficits in visual function (e.g. contrast,
visual fields, accommodation and refractive errors)
[140, 141, 145]. In addition, neuro-ophthalmic manifesta-
tions such as strabismus and nystagmus have been descri-
bed [141]. Risk factors predicting ocular manifestations of
CZS include maternal first trimester infection and presence
of microcephaly at birth.
Confirmative diagnosis of ZIKV infection requires labora-
tory testing of whole blood or urine, and is also possible in
other bodily fluids [117]. For instance, ocular fluid testing has
aided diagnosis in ZIKV anterior uveitis [131]. Testing mod-
alities include RT-PCR, ELISA and Zika plaque reduction
neutralization test (PRNT) [146]. No specific vaccines or
antiviral drugs are currently available, and treatment is sup-
portive. Regarding CZS, the French Ministry of Health and
CDC recommend mandatory comprehensive ophthalmic
screening in all children born to a mother infected during
pregnancy, prior to 1 month of age, with a further fundus
exam repeated at 1 year [147, 148]. Early detection and
expedient refractive correction can lead to immediate
improvements in visual function in these children [149].
West Nile (Flaviviridae)
West Nile virus (WNV) is an enveloped, positive-sense, single-
stranded RNA virus of the Flaviviridae family, and a member
of the Japanese encephalitis serocomplex of viruses [150].
WNV has five distinct phylogenetic lineages with only lineage
one, distributed worldwide, and two, enzootic in Africa, known
to cause disease in humans [150, 151]. The natural reservoir of
WNV is birds, with transmission to humans occurring via
Culex mosquitoes. Bird–mosquito–human transmission leads
to the vast majority of disease in humans [150, 152].
Of patients who contract the virus, ~75% are asymptomatic,
25% develop West Nile fever (WNF) and <1% a neuroinva-
sive disease fatal in 10% [150, 153–155]. After an incubation
period of around 2–14 days, WNF presents as a self-limiting,
non-specific viral illness including fever, headache, fatigue,
nausea and vomiting, lymphadenopathy and skin rash, that
typically lasts less than a week [150]. Neuroinvasive disease
causes meningitis, encephalitis, acute flaccid paralysis,
movement disorders or other neurological manifestations
[150, 156]. Advanced age is the strongest predictor of severe
neurological manifestations and fatality [150].
Multifocal chorioretinitis (Fig. 4D) is the most common
ocular finding in WNV, typically bilateral, and occurring in
23 of 29 (79%) consecutive patients with laboratory con-
firmed WNV in the largest relevant prospective study to
date [157]. Patients are frequently asymptomatic, though
symptoms can include floaters, reduced visual acuity, red-
ness, ocular pain, visual field defects or diplopia [157, 158].
Fig. 4 West Nile virus
retinopathy. A Inflammatory




Hasburn [232] (CC-BY licence).
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The multifocal chorioretinitis involves 10–50 deep, flat,
white or yellowish lesions per eye ranging from
100–1500 µm in diameter, typically arranged in a curvi-
linear cluster in the mid-periphery [109, 157]. Lesions tend
to self-resolve without residual pigmentation and visual
acuity typically returns to baseline [151, 158–160]. On
fluorescein angiography, the active lesions are hypo-
fluorescent initially and later hyperfluorescent. Inactive
lesions have a target-like, rosette appearance [109, 161].
Chorioretinitis appears more frequently in those aged over
50 and those with diabetes mellitus [162, 163]. Other ocular
manifestations include occlusive retinal vasculitis and
intraretinal haemorrhages, optic neuritis, congenital chor-
ioretinal scarring and uveitis (Fig. 4) [157, 158, 162].
Diagnosis is typically confirmed by laboratory testing
using ELISA to detect IgM in serum of cerebrospinal fluid,
and in limited scenarios supported by RT-PCR. There is no
vaccine, treatment is supportive, with vector control as the
mainstay of prevention [150].
Yellow fever virus (Flaviviridae)
The yellow fever virus (YFV) is an enveloped, positive-
sense, single-stranded RNA virus of the Flaviviridae family.
It is an arbovirus transmitted to humans primarily through
the bite of infected Aedes or Haemagogus species mos-
quitoes, and principally maintained by a sylvatic (jungle)
transmission cycle between mosquitoes and non-human
primates and mosquito–human transmission cycles in urban
areas, the latter leading to outbreaks of yellow fever (YF) in
human populations. Dozens of countries in both Africa and
South and Central America are endemic for YF, leading to
an estimated 30,000–60,000 fatalities per year [164].
The majority infected with YFV are asymptomatic or
exhibit an initial phase of non-specific viral symptoms after
3–6 days (fever, myalgia, nausea and vomiting), which then
resolves within days. After less than a day of resolution,
15–25% of patients develop a toxic form of the disease,
with fever, a haemorrhagic diathesis and multi-organ failure
(especially renal and hepatic) leading to a 50% mortality
rate [165, 166].
A common ocular finding in the initial phase is con-
junctivitis, whilst scleral icterus is often a feature of the
toxic phase [109, 166]. A small number of case reports
suggest other ocular manifestations, with two intensive care
patients reported in Brazil noted to present with bilateral
increased choroidal thickness. One subsequently develops
bilateral retinal vein congestion. The other developed
bilateral mid-peripheral 360° detachment of the choroid and
yellowish sub-retinal lesions. In another reported case,
unilateral retinal oedema, macular exudates and haemor-
rhages were found during the convalescent stage, poten-
tially due to immune-mediated causes [167].
There also exist case reports of ocular disorders asso-
ciated with YFV vaccination, especially when the live YFV
vaccine is combined with other vaccines, such as Neisseria
Meningitidis, Hepatitis A/B or Typhoid. The reported
complications are varied and include uveitis, unilateral optic
neuropathy, evanescent white dot syndrome, multifocal
choroiditis, arteriolar occlusion and even a
Vogt–Koyanagi–Harada-like disease (with accompanying
serous retinal detachment and choroidal thickening)
[109, 168, 169]. These conditions are rarely reported and
most often self-limiting with a favourable course over a few
weeks with simple supportive anti-inflammatory treatment.
Diagnosis of YFV relies on PCR of blood or urine
samples in the early stages, and ELISA or PRNT to detect
antibodies in later stages. Treatment is mainly supportive,
with a strong emphasis on prevention through public health
measures and vaccination [166, 170].
Chikungunya (Togaviridae)
Chikungunya virus (CHIKV) is an enveloped, positive-
sense, single-stranded RNA virus belonging to the genus
Alphavirus of the family Togaviridae. CHIKV has been
identified in over 60 countries in Asia, Africa, Europe and
the Americas, and several epidemics have been reported in
the past 20 years commonly during monsoon season.
CHIKV is principally transmitted by the bite of the mos-
quitoes of the Aedes genus—Aedes aegypti and Aedes
albopictus are the primary vectors [171]. Transplacental
transmission has been reported, without significant out-
comes for mother and child [172].
CHIKV infection results primarily in an acute fever with
a severe polyarthralgia predominating in the distal extre-
mities that may persist for several weeks or months [173].
Cervical or generalized lymphadenopathy may be present,
along with various mucocutaneous manifestations. Neuro-
logic complications such as meningoencephalitis or other
multi-organ failure are rare, though described in the
immunocompromised and at the extremes of age. There is
an overall mortality rate of 1 in 1000, largely restricted to
the elderly [174]. However, often symptoms are mild and
may resolve unrecognized, or be misdiagnosed in areas
where dengue occurs.
CHIKV has a variety of ocular manifestations ranging
from conjunctivitis to retinitis. Photophobia, conjunctival
hyperaemia and retro-orbital pain are frequent in the acute
phase, and may be isolated without other ocular involve-
ment. Anterior uveitis is the most frequently reported ocular
complication (one in three ocular cases), appearing
4–12 weeks after disease onset [175]. The anterior uveitis
may be either granulomatous or non-granulomatous, and
may be associated with elevated intraocular pressure, or
more infrequently with posterior synechiae. A Fuchs’
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uveitis phenotype of fine stellate keratic precipitates is
visualised on confocal microscopy, with a diffuse distribu-
tion over the posterior cornea (Fig. 5) [109]. Although
presence of CHIKV RNA has been documented by PCR
analysis of aqueous samples in some patients with anterior
uveitis and previous CHIKV fever, it is unclear whether this
is pathogenic or merely a remnant of recent systemic illness
[176]. The uveitis responds well to steroid drops and anti-
glaucoma drops if required, and complete resolution is
achieved in <3 weeks [177].
Posterior uveitis often presents weeks after the acute
symptoms, as retinitis, multifocal choroiditis or neuror-
etinitis. Neuroretinitis involves exudative haemorrhagic
lesions essentially localized to the posterior pole, which can
be associated with intra-/sub-retinal macular oedema [178].
The lesions are hypofluorescent in the early phases and
hyperfluorescent in the late phases of fluorescein angio-
graphy (Fig. 6). The optic disc is hyperaemic, and the
vitreous shows a slight inflammatory reaction. Empiric
treatment with acyclovir (ineffective against RNA viruses),
systemic steroids and non-steroidal anti-inflammatory drops
can lead to favourable outcomes in <2 months, though
recurrence of retinitis has been reported [177, 179, 180].
Optic neuropathy is evident in 10% of cases with ocular
involvement, developing typically 1 month after disease
onset [109]. In one case series of 14 CHIKV+ patients with
clinical features suggestive of optic neuritis, all complained
of a severe decrease in visual acuity and earlier initiation of
treatment with IV methylprednisolone was associated with
improved visual recovery [181]. The underlying mechanism
may involve direct viral involvement (as in some cases, the
onset of optic neuropathy is coincident with that of systemic
signs) or an immune mechanism (as in the majority, where
delayed onset, bilateral involvement and a good response to
steroid treatment has been observed). Other ocular lesions
have also been described: keratitis, scleritis and episcleritis,
lagophthalmos and oculomotor palsies [109]. The presence
of CHIKV has been demonstrated in the cornea during the
viraemic phase, resulting in exclusion from corneal dona-
tion in endemic areas [182].
Fig. 5 Chikungunya, slit lamp anterior segment photos with 1+
cells and 2+ flare evident in the anterior chamber of both eyes. A
Pigmented keratic precipitates in the inferior cornea, B stellate keratic
precipitates. Source: Mahendradas [233] (CC-BY Licence).
Fig. 6 Chikungunya, retinal manifestations. A Fundus image of the
left eye showing confluent area of retinal whitening suggestive of
retinitis. B, C Fundus fluorescein angiography showing the posterior
pole in early and late hypofluorescence, respectively. Source:
Mahendradas [233] (CC-BY Licence).
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Formal diagnosis of CHIKV in the initial 8 days of acute
infection is done by RT-PCR or direct isolation of virus/
viral antigens, following which serological testing with
ELISA is recommended [183]. Case reports highlight that
RT-PCR may detect CHIKV RNA in aqueous fluid [184].
Antiviral drug and vaccine development are underway
[185, 186].
Crimean Congo* (Nairoviridae)
Crimean-Congo haemorrhagic fever virus (CCHFV) is an
enveloped, circular, negative-sense, single-stranded RNA
virus in the Nairoviridae family, which causes an acute viral
haemorrhagic fever. Transmission of the virus is primarily
through tick bites belonging to the genus Hyalomma,
which are widely distributed in Asia, Africa and Eastern
Europe [187]. Transmission is also reported to occur by
contact with patients or animals with a high viral load, thus
posing a high risk of transmission in healthcare environ-
ments [188].
An estimated 90% of patients are oligo- or asymptomatic
whilst the remaining 10% can present with the more severe
form of disease described in many studies [189]. The dis-
ease manifests as sudden onset fever, myalgia and dizziness.
Some develop gastro-intestinal symptoms such as vomiting
and stomach pain. After 3–5 days, the haemorrhagic phase
starts including bleeding (severe bruising and epistaxis),
confusion and hepatomegaly. Fatality rates for hospitalised
patients are documented as ranging from 9 to 50% [190].
Only one study has formally characterised the ocular
findings in CCHFV patients after previous studies reported
conjunctival injection and photophobia [191]. In a case
series of 19 patients, none had ocular complaints, but
examination showed that 14 (73.7%) had ocular abnorm-
alities. Subconjunctival haemorrhage was present in 12
(63.2%) patients and retinal haemorrhage was present in 7
(36.8%) patients. Subconjunctival haemorrhage was pete-
chial, occurring most often at the nasal quadrant and peri-
limbal area of both eyes. Retinal haemorrhage was dot-like
or triangular at the paramacular and peripapillary area.
The ocular findings did not appear to correlate with disease
severity. Both types of haemorrhage had resolved com-
pletely at 1 month follow-up. The results of this small study
indicate that CCHF should be considered in the differential
when subconjunctival or retinal haemorrhages are seen
along with fever in travellers from endemic areas [191].
Diagnosis is via serum RT-PCR in the early stages of
disease or ELISA late in disease and treatment is largely
supportive with some evidence that ribavirin shows some
benefit [192, 193]. After people of working age exposed to
tick populations, healthcare workers are the second most-
affected group [192]. Knowledge of CCHFV may therefore
help prevent nosocomial spread of the virus.
Droplet
Coronavirus disease 2019 (COVID-19)*
(Coronaviridae)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) is an enveloped, single-stranded, positive-sense, RNA virus
of the family coronaviridae [194]. SARS-CoV-2 emerged as
the cause of coronavirus disease 2019 (COVID-19) in
December 2019 in Wuhan, China. The subsequent pandemic
of this highly transmissible virus has caused in excess of
1250,000 deaths at the time of writing, and poses an ongoing
threat to global public health [195]. The main modes of
transmission are respiratory droplets and direct contact [196].
COVID-19 has a viral pneumonia picture. Early symp-
toms occur after a median incubation period of 4 days, most
commonly fever, cough and fatigue [197]. In a proportion
of cases, a severe form of the disease ensues, with pro-
gression to an acute respiratory distress syndrome picture
and type 1 respiratory failure. In such cases, hospitalisation
is required for oxygen supplementation, and/or intubation
and ventilation. Increased age and co-existing illness are
associated with increased severity of disease [197].
Viral RNA has been detected in ocular secretions
[7, 198]. Several reports have suggested that SARS-CoV-2
can cause a mild follicular conjunctivitis, with symptoms
including conjunctival hyperaemia, chemosis, epiphora and
increased secretion. Twenty-three cases have been descri-
bed so far in published literature, and three cases in pre-
published studies [7, 197–201]. The largest study reporting
cases described conjunctival congestion in 9 of 1099
patients (0.8%) [197]. There has been only one study
showing retinal changes in COVID-19 patients [202].
Twelve COVID-19 patients examined in the study all dis-
played hyper-reflective changes in retinal ganglion cell and
inner plexiform layers binocularly using OCT. Four patients
had cotton wool spots and microhaemorrhages but no signs
of intraocular inflammation. Despite OCT changes in the
retina, no visual acuity nor pupillary reflex changes
was found.
RT-PCR of oropharyngeal and nasopharyngeal swabs is
the mainstay of testing, with other sources sampled less
commonly. However, false negatives present a problem and
so clinical suspicion based on symptomatology, biochem-
istry and imaging findings play an important role. Many
clinical trials are already underway to assess potential
treatment options and trials have begun for candidate vac-
cines [202].
Influenza A H1N1 (Orthomyxoviridae)
Influenza A H1N1 is an enveloped, negative-sense, single-
stranded RNA virus of the orthomyxoviridae family. The
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subtype of Influenza A relates to cell surface glycoproteins.
Influenza A undergoes continuous antigenic drift causing
seasonal influenza, and sporadic antigenic shifts causing
pandemics [203]. Notable pandemics include the 1918
Spanish flu and 2009 Swine flu (A(H1N1)pdm09 virus).
Since then H1N1 has been identified in normal seasonal flu
along with H3N2 [204]. A global average of
294,000–518,000 respiratory deaths is associated with
seasonal influenza annually [205]. The virus spreads pri-
marily via droplet transmission though there is a role for
indirect contact transmission [206]. Ex vivo cultures have
also found that the A(H1N1)pdm09 subtype has the ability
to replicate in the human conjunctiva highlighting the
conjunctiva as a potential route of infection [207].
Common symptoms include fever, cough, sore throat,
coryza, myalgia, headaches and fatigue, and the disease is
usually self-limiting [208]. The most common complica-
tions are viral pneumonia or secondary bacterial pneumo-
nia. Other complications include myositis, rhabdomyolysis,
myocarditis, pericarditis, encephalitis, transverse myelitis
and Guillain-Barre syndrome [208]. In elderly and other
high-risk individuals, deterioration of underlying cardio-
vascular, pulmonary and renal function may lead to irre-
versible changes and death [209].
Ocular involvement in influenza A virus disease is
common often involving mild conjunctivitis to reports of
more severe eye involvement. True prevalence of ocular
manifestations is difficult to ascertain from isolated studies
due to lack of thorough ophthalmoscopic examinations
during influenza outbreaks, and the benign nature of the
disease in most patients. This accounts for the paucity of
literature and detailed retinal findings [209].
A growing body of evidence highlights the potential
ocular findings in influenza A H1N1 disease. A case series
of 89 patients with H1N1 infection found that acute
conjunctivitis was the most common finding occurring
bilaterally in 65.17% of patients and unilaterally in 12.36%
patients [210]. Features of significant eyelid oedema, con-
junctival hyperaemia, watery discharge and moderate che-
mosis with sub-tarsal follicles were evident in most patients.
Ten cases of conjunctivitis were severe and two were hae-
morrhagic with sub-tarsal petechial haemorrhage, with such
findings imaged elsewhere (Fig. 7). The condition resolved
with topical NSAIDs and topical ganciclovir. Corneal
involvement was present in eighteen (20.22%) patients.
Fluorescein staining revealed multiple bilateral corneal
erosions that resolved by day 7. Iridocyclitis is a much rarer
reported anterior segment finding [209].
Involvement of the posterior segment is less frequent.
However, there have been reports of uveal effusion syn-
drome, retinopathy, retinitis and optic neuritis [210–216].
Uveal effusion syndrome occurs around 2 days after flu-like
symptoms. Painful red eye, reduced visual acuity, a quiet
shallow anterior chamber, and swelling of the posterior
chamber and vitreous cells indicative of sub-retinal exuda-
tion, are reported [210, 211]. Treatment with topical and
systemic corticosteroids improved the condition in 10 days
[210]. Visual defects from retinopathy usually self-resolve
in 3 weeks; however, steroids may play a role in the treat-
ment of severe cases [210, 212, 214]. One case of retinal
vasculitis occurred without recovery of vision despite ster-
oid therapy [217]. Optic neuritis has been reported with
steroid therapy improving the condition [210, 216, 218].
Reports of encephalopathy associated with cortical visual
loss and oculomotor palsy is also possible [219–221].
Diagnosis is made clinically except in certain scenarios
where testing may influence clinical decisions, such as whe-
ther to initiate antiviral treatment, perform other diagnostic
testing or to implement infection prevention and control
measures [222]. Recommended diagnostic tests include rapid
Fig. 7 Influenza virus H1N1, severe ocular cases. A Lower chemosis and severe conjunctival hyperaemia associated with significant eyelid
oedema, B petechiae and significant upper sub-tarsal follicles. Source: Lopez-Pratz [234] (CC-BY Licence).
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molecular assays for outpatients and RT-PCR is recom-
mended for hospitalised patients, using nasopharyngeal, nasal
or throat swabs [223]. Awareness of ocular symptoms in
influenza A virus infection may facilitate early intervention
with steroids, antiviral drugs and topical treatments to prevent
long-term visual damage in severe cases of H1N1. Both
strains of seasonal influenza H1N1 and H3N2 are targeted in
the annual influenza vaccinations [200, 201].
Prevention and treatment
These emerging viruses pose a major public health risk due to
their known pandemic potential and/or insufficient counter
measures. Notably, these pathogens are all RNA viruses,
whose error prone RNA-dependent RNA polymerase
enzymes result in inherently high mutability and capacity for
host immune evasion, which may underlie their pandemic
potential [224]. Continued discovery and development of new
antiviral medications and vaccines are a research priority for
global health, particularly as new pathogens periodically
emerge and old ones evolve to evade current therapeutic
agents. For the viruses discussed in this review, the avail-
ability of approved antiviral therapies and vaccines is limited
(with approval only for influenza A H1N1 and Ebola vac-
cines); however, a number is currently under development.
In the absence of specific antiviral drugs or immunisa-
tion, precautionary strategies are the mainstay for curbing
transmission. These include vector control and exposure
limitation, screening and prophylaxis of exposed indivi-
duals, isolation of infected individuals and potential con-
tacts, precautions depending on transmission route, and
both personal and environmental hygiene and decontami-
nation. Strategies for pandemic preparedness also need to be
capable of mitigating risks posed by yet to emerge,
unknown viruses, as reflected by inclusion of “Disease X”
on WHO’s shortlist of blueprint priority diseases.
Many of these viruses confer potential risk to eye care
providers. Isolation of viral RNA from ocular secretions has
been confirmed in humans for Ebola, Marburg, Zika, Chi-
kungunya, COVID and influenza A H1N1, as well as in
animal models of LF [7, 20, 21, 30, 118, 119, 184, 198,
207, 225, 226]. This possibility remains to be further
investigated for Nipah, RVF, Dengue, West Nile and
Crimean Congo virus. Together, these highlight the need for
extra precautions during ophthalmic procedures in certain
cases, along with advisory eye protection to limit contagion.
Eye specialists are at particular risk due to the close
proximity during eye examination and the potential for ‘air
puff’ tonometry to generate droplets or aerosols [227].
General precautions in ophthalmic practice includes instal-
lation of transparent shields on slit-lamps, disinfection of
surfaces and instruments after each use, donning of
protective equipment, appropriate triaging and imple-
mentation of telemedicine where appropriate [228, 229].
Given the variations in practice patterns, practitioners
should heed their respective best-practice guidelines for
infection control.
Summary
The threat of emerging viral disease has been made all the
more clear in the midst of the current COVID-19 pandemic.
Further, the possibility that a yet unknown pathogen could
cause a future epidemic has also been acknowledged by the
WHO on their shortlist of blueprint priority diseases as
‘Disease X’. It has been estimated that there are 1.67 million
unknown viruses circulating in animal reservoirs and there
remains the potential for them to evolve and transmit to
humans [230]. It is interesting that the majority of new
‘threats’ have ocular manifestations.
Ophthalmologists should therefore be mindful of the
variation of presentations of eye diseases in this context.
The COVID-19 pandemic and studies of other viral diseases
highlight that globalisation and modernisation play a sig-
nificant role in the spread of viral disease and consequently
returning travellers could present with manifestations of
both current known and novel viral diseases. An awareness
of the ocular manifestations of emerging viral diseases can
therefore enable eye specialists to facilitate swift diagnosis,
improve clinical outcomes and contribute to wider public
health efforts during outbreaks.
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